Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

被引:468
作者
Jiang, Ningni [1 ,2 ,3 ]
Dai, Qijie [1 ,2 ,3 ]
Su, Xiaorui [1 ,2 ,3 ]
Fu, Jianjiang [1 ,2 ,3 ]
Feng, Xuancheng [1 ,2 ,3 ]
Peng, Juan [1 ,2 ,3 ,4 ]
机构
[1] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Peoples R China
[2] Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China
[3] Guangdong Higher Educ Inst, Key Lab Reprod & Genet, Guangzhou 510150, Peoples R China
[4] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA
基金
中国国家自然科学基金;
关键词
PI3K; AKT; PTEN; Cancer; Targeted therapy; EPITHELIAL-MESENCHYMAL TRANSITION; PROMOTES CELL-PROLIFERATION; PAPILLARY THYROID-CANCER; ACUTE MYELOID-LEUKEMIA; PROTEIN-KINASE B; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; AKT INHIBITOR AFURESERTIB; HUMAN BLADDER-CANCER; PROSTATE-CANCER; SIGNALING PATHWAY;
D O I
10.1007/s11033-020-05435-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in various human cancers. We state the abnormalities of PI3K/AKT pathway in different cancers, which are closely related with tumorigenesis, proliferation, growth, apoptosis, invasion, metastasis, epithelial-mesenchymal transition, stem-like phenotype, immune microenvironment and drug resistance of cancer cells. In addition, we investigated the current clinical trials of inhibitors against PI3K/AKT pathway in cancers and found that the clinical efficacy of these inhibitors as monotherapy has so far been limited despite of the promising preclinical activity, which means combinations of targeted therapy may achieve better efficacies in cancers. In short, we hope to feature PI3K/AKT pathway in cancers to the clinic and bring the new promising to patients for targeted therapies.
引用
收藏
页码:4587 / 4629
页数:43
相关论文
共 400 条
[1]  
ADAMO B, 2011, BREAST CANCER RES, V13
[2]   Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 [J].
Agrawal, Nishant ;
Frederick, Mitchell J. ;
Pickering, Curtis R. ;
Bettegowda, Chetan ;
Chang, Kyle ;
Li, Ryan J. ;
Fakhry, Carole ;
Xie, Tong-Xin ;
Zhang, Jiexin ;
Wang, Jing ;
Zhang, Nianxiang ;
El-Naggar, Adel K. ;
Jasser, Samar A. ;
Weinstein, John N. ;
Trevino, Lisa ;
Drummond, Jennifer A. ;
Muzny, Donna M. ;
Wu, Yuanqing ;
Wood, Laura D. ;
Hruban, Ralph H. ;
Westra, William H. ;
Koch, Wayne M. ;
Califano, Joseph A. ;
Gibbs, Richard A. ;
Sidransky, David ;
Vogelstein, Bert ;
Velculescu, Victor E. ;
Papadopoulos, Nickolas ;
Wheeler, David A. ;
Kinzler, Kenneth W. ;
Myers, Jeffrey N. .
SCIENCE, 2011, 333 (6046) :1154-1157
[3]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[4]   Mechanisms of PTEN loss in cancer: It's all about diversity [J].
Alvarez-Garcia, Virginia ;
Tawil, Yasmine ;
Wise, Helen M. ;
Leslie, Nicholas R. .
SEMINARS IN CANCER BIOLOGY, 2019, 59 :66-79
[5]   Hodgkin Lymphoma: Diagnosis and Treatment [J].
Ansell, Stephen M. .
MAYO CLINIC PROCEEDINGS, 2015, 90 (11) :1574-1583
[6]   Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway [J].
Aravinth, Sneha Priya ;
Rajendran, Sakthi ;
Li, Yating ;
Wu, Meihui ;
Wong, Anna Hiu Yi ;
Schwarz, Herbert .
LEUKEMIA & LYMPHOMA, 2019, 60 (11) :2697-2704
[7]   Non-Hodgkin lymphoma [J].
Armitage, James O. ;
Gascoyne, Randy D. ;
Lunning, Matthew A. ;
Cavalli, Franco .
LANCET, 2017, 390 (10091) :298-310
[8]   Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application [J].
Aronson, L. I. ;
Davenport, E. L. ;
Mirabella, F. ;
Morgan, G. J. ;
Davies, F. E. .
LEUKEMIA, 2013, 27 (12) :2397-2403
[9]   Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α [J].
Baer, Romain ;
Cintas, Celia ;
Dufresne, Marlene ;
Cassant-Sourdy, Stephanie ;
Schoenhuber, Nina ;
Planque, Laetitia ;
Lulka, Hubert ;
Couderc, Bettina ;
Bousquet, Corinne ;
Garmy-Susini, Barbara ;
Vanhaesebroeck, Bart ;
Pyronnet, Stephane ;
Saur, Dieter ;
Guillermet-Guibert, Julie .
GENES & DEVELOPMENT, 2014, 28 (23) :2621-2635
[10]   Prevention of Prostate Cancer Morbidity and Mortality Primary Prevention and Early Detection [J].
Barry, Michael J. ;
Simmons, Leigh H. .
MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (04) :787-+